INFECTION WITH CLOSTRIDIUM DIFFICILE: RISK FACTORS AND PHARMACOTHERAPEUTIC MANAGEMENT (submitted in 2019)
5PSQ-107
ACTIVE PHARMACOVIGILANCE AND DEDICATED PHARMACIST: THE EXPERIENCE OF A TERRITORIAL HEALTHCARE HOSPITAL (submitted in 2019)
5PSQ-106
ANALYSIS OF HANDLING OF HAZARDOUS DRUGS IN A NURSING HOME (submitted in 2019)
5PSQ-105
PREVENTING FALLS IN ORTHOGERIATRIC PATIENTS BY MANAGING THEIR THERAPEUTIC PROFILES (submitted in 2019)
5PSQ-104
DESCRIPTION OF A PHARMACOVIGILANCE PROGRAMME IN A TERTIARY HOSPITAL (submitted in 2019)
5PSQ-103
EXPERIENCE OF ANTIFIBROTIC AGENTS IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (submitted in 2019)
5PSQ-102
AMBULATORY SUBCUTANEOUS BIOLOGIC THERAPY OPTIMISATION IN RHEUMATOLOGY: IMPLEMENTATION OVER TIME (submitted in 2019)
5PSQ-101
DRUG-DRUG INTERACTIONS AND POTENTIALLY RELATED ADVERSE CLINICAL EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASES (submitted in 2019)
5PSQ-100
COMPARATIVE ANALYSIS OF THE SAFETY AND TOLERABILITY PROFILE OF PIRFENIDONE AND NINTEDANIB IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (submitted in 2019)
5PSQ-099
POTENTIALLY INADEQUATE MEDICATION– DETECTED DIFFERENTLY BY PRISCUS, FORTA OR EU(7)-PIM – IS ASSOCIATED WITH REDUCED COGNITIVE FUNCTION IN MULTIMORBID ELDERLY PATIENTS (submitted in 2019)
5PSQ-098
ALLERGIES AND INTOLERANCES: AN OPPORTUNITY FOR IMPROVEMENT (submitted in 2019)
5PSQ-097
POTENTIALLY HARMFUL EXCIPIENTS IN NEONATAL AND PAEDIATRIC PATIENTS (submitted in 2019)
5PSQ-096
HAZARD VULNERABILITY ANALYSIS TO EVALUATE RISK OF DRUG SHORTAGES ACCORDING TO THE THERAPEUTIC CLASS (submitted in 2019)
5PSQ-095
ANALYSIS OF THE TOXICITIES ASSOCIATED WITH TYROSINE KINASE INHINITORS IN PATIENTS WITH CHRINIC MYELOID LEUKAEMIA (submitted in 2019)
5PSQ-094
HOW CAN PATIENT HELD INFORMATION ABOUT MEDICATION IMPROVE PATIENT SAFETY? (submitted in 2019)
